WEBULL
News
IDXG
1.140
NaN%
--
Weekly Report: what happened at IDXG last week (1208-1212)?
Weekly Report · 3d ago
Weekly Report: what happened at IDXG last week (1201-1205)?
Weekly Report · 12/08 10:16
Interpace Biosciences Repays Loan Early for Growth
TipRanks · 12/03 21:34
Weekly Report: what happened at IDXG last week (1124-1128)?
Weekly Report · 12/01 10:12
Weekly Report: what happened at IDXG last week (1117-1121)?
Weekly Report · 11/24 10:16
Weekly Report: what happened at IDXG last week (1110-1114)?
Weekly Report · 11/17 10:16
Interpace Biosciences GAAP EPS of $0.04, revenue of $8.76M
Seeking Alpha · 11/13 05:54
Interpace Biosciences Reports Q3 2025 Earnings
TipRanks · 11/13 03:59
Weekly Report: what happened at IDXG last week (1103-1107)?
Weekly Report · 11/10 10:14
Weekly Report: what happened at IDXG last week (1027-1031)?
Weekly Report · 11/03 10:14
Weekly Report: what happened at IDXG last week (1020-1024)?
Weekly Report · 10/27 10:17
Weekly Report: what happened at IDXG last week (1013-1017)?
Weekly Report · 10/20 10:14
Weekly Report: what happened at IDXG last week (1006-1010)?
Weekly Report · 10/13 10:16
Weekly Report: what happened at IDXG last week (0929-1003)?
Weekly Report · 10/06 10:13
Weekly Report: what happened at IDXG last week (0922-0926)?
Weekly Report · 09/29 10:14
Weekly Report: what happened at IDXG last week (0915-0919)?
Weekly Report · 09/22 10:14
Interpace Biosciences presents two posters at ATA meeting
TipRanks · 09/15 13:20
Weekly Report: what happened at IDXG last week (0908-0912)?
Weekly Report · 09/15 09:28
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
Barchart · 09/15 08:15
Weekly Report: what happened at IDXG last week (0901-0905)?
Weekly Report · 09/08 09:29
More
Webull provides a variety of real-time IDXG stock news. You can receive the latest news about Interpace Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About IDXG
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.